DiscGenics closed a US $14MM Series B financing. The company is pursuing dual regulatory tracks in the U.S. and Japan for its IDCT product candidate, an injectable cell therapy to treat degenerative disc disease. Funds will support this and a manufacturing ramp-up for Phase III clinical and commercial production.
The round brings DiscGenics’ total funding to $21.7MM, and was jointly led by its Board of Directors, existing long-term investors and new investment partner Mitsubishi UFJ Capital.
DiscGenics holds patents in the U.S. and seven EU markets, as well as China, Israel and Japan.
DiscGenics closed a US $14MM Series B financing. The company is pursuing dual regulatory tracks in the U.S. and Japan for its IDCT product candidate, an injectable cell therapy to treat degenerative disc disease. Funds will support this and a manufacturing ramp-up for Phase III clinical and commercial production.
The round brings DiscGenics'...
DiscGenics closed a US $14MM Series B financing. The company is pursuing dual regulatory tracks in the U.S. and Japan for its IDCT product candidate, an injectable cell therapy to treat degenerative disc disease. Funds will support this and a manufacturing ramp-up for Phase III clinical and commercial production.
The round brings DiscGenics’ total funding to $21.7MM, and was jointly led by its Board of Directors, existing long-term investors and new investment partner Mitsubishi UFJ Capital.
DiscGenics holds patents in the U.S. and seven EU markets, as well as China, Israel and Japan.
Copy to clipboard 
